An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure
Abstract
Background In diabetes, poor glycemic control, as indexed by hemoglobin A1c (HbA1c), is associated with increased risk of cardiovascular events and new-onset heart failure (HF). However, in patients with diabetes and HF, the relationship between glucose control and survival has not been investigated. Our study aimed to evaluate the relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic HF.Methods We studied a cohort of 123 patients with diabetes and advanced systolic HF referred to a single center with HbA1c values measured at presentation. The patients were grouped based on HbA1c: HbA1c < or = 7.0 (n = 49) and HbA1c > 7.0 (n = 74).Results The cohort was 70% men, ejection fraction of 25% +/- 7, 59% ischemic etiology, HbA1c 7.9 +/- 1.8, and diabetes duration of 8.6 +/- 9.0 years. The HbA1c groups were similar in age; sex; New York Heart Association class; body mass index; diabetes duration; and insulin, metformin, and glitazone use. HbA1c > 7.0 was associated with higher ejection fraction, increased beta-blocker, and sulfonlyurea use. Patients with HbA1c < or = 7.0 had significantly increased all-cause mortality, compared with those with HbA1c > 7.0 (35% vs 20%, hazard ratio 2.6, 95% CI 1.3-5.2, P < .01). In multivariate analysis, HbA1c < or = 7.0 remained associated with increased mortality (hazard ratio 2.3, 95% CI 1.0-5.2).Conclusions Paradoxically, elevated HbA1c levels were associated with improved survival in this cohort of patients with diabetes and advanced HF. Further investigation is necessary to determine the nature of this relationship and optimal HbA1c in patients with diabetes and HF.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In one single-centre observational study of 123 young patients with advanced HF and T2DM, patients with a HbA1c of <7% had higher rates of all-cause mortality.
“In one single-centre observational study of 123 young patients with advanced HF and T2DM, patients with a HbA 1c of <7% had higher rates of all-cause mortality.106”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [106]
The citation lists haven’t been fetched yet
References 38 · Cited by 145
- Authors
- Eshaghian, S., Horwich, T. B., & Fonarow, G. C.
- Affiliations
- Cedars-Sinai Medical Center (US)
- University of California, Los Angeles (US)
- Corresponding author
- Fonarow, Gregg C.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 151
- Issue
- 1
- Pages
- 91.e1-91.e6
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2108648971
- Cited by
- 145
- References
- 38
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 2 · 2019: 13 · 2018: 12 · 2017: 7 · 2016: 13 · 2015: 7 · 2014: 5 · 2013: 2 · 2012: 12
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (401357JI30608)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- HbA1c, glycemic control, diabetes mellitus, heart failure with reduced ejection fraction, advanced heart failure, mortality, all-cause mortality, ejection fraction, beta-blockers, sulfonamides, metformin, insulin, thiazolidinediones
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Heart Failure, Glycated Hemoglobin, Humans, Male, Middle Aged, Protein Precursors, Systole, Survival Rate, Disease Progression, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review